Education
| School — Major — Degree | Duration |
|---|---|
|
國立中山大學 — 生物醫學研究所(畢) — 博士 Doctorate, Institute of Biomedical Sciences, National Sun Yat-sen University |
2011/09 — 2017/03 |
|
國立臺灣大學 — 口腔生物科學研究所(畢) — 碩士 Master, Graduate Institute of Oral Biology, National Taiwan University |
2009/09 — 2011/06 |
|
高雄醫學大學 — 生物醫學暨環境生物學系(畢) — 學士 Bachelor, Department of Biomedical Science and Environment Biology, Kaohsiung Medical University |
2005/09 — 2009/06 |
Intramural Experience
| Office/Department/Institute | Position | Duration |
|---|---|---|
| 學士後醫學系 School of Post-Baccalaureate Medicine | Associate Professor | 2022/08/01 — |
| 學士後醫學系 School of Post-Baccalaureate Medicine | Assistant Professor | 2020/08/01 — 2022/07/31 |
| 實驗診斷學科 Department of Laboratory Medicine | Assistant Professor | 2018/02/01 — 2020/07/31 |
Extramural Experience
Discipline
| NO | Discipline | Expertise |
|---|---|---|
| 1 | 生物醫農類 Biology, Medicine and Agriculture | 生物學之生化及分子生物 Biochemistry and Molecular Biology |
Research & Technology Platform Open to the Outside
Interested Area(s)for Interdisciplinary Research
基因檢測、抗體藥物開發、蛋白藥物開發
Genetic diagnosis, Antibody drugs development, protein drugs development
Area(s) of Expertise & Research
免疫學、蛋白質體學、分子細胞生物學、實驗診斷學蛋白質藥物開發、分子免疫學、抗體基因工程、腫瘤生物學、臨床檢測
Protein drugs development, Molecular immunology, Antibody engineering, Cancer biology, clinical diagnosis
Publication
| NO | Publication |
|---|---|
| 1 | Development of NS2B-NS3 protease inhibitor that impairs Zika virus replication. Development of NS2B-NS3 protease inhibitor that impairs Zika virus replication. |
| 2 | A lesion selective albumin CTLA4Ig as a safe and effective treatment for collagen induced arthritis A lesion selective albumin CTLA4Ig as a safe and effective treatment for collagen induced arthritis |
| 3 | A Low-Cost, Sensitive Reporter System Using Membrane-Tethered Horseradish Peroxidase for Efficient Gene Expression Analysis A Low-Cost, Sensitive Reporter System Using Membrane-Tethered Horseradish Peroxidase for Efficient Gene Expression Analysis |
| 4 | Inhibition of gut microbial β-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesis. Inhibition of gut microbial β-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesis. |
| 5 | Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group |
| 6 | Structural insights into Nirmatrelvir (PF-07321332)-3C-like SARS-CoV-2 protease complexation: a ligand Gaussian accelerated molecular dynamics study. Structural insights into Nirmatrelvir (PF-07321332)-3C-like SARS-CoV-2 protease complexation: a ligand Gaussian accelerated molecular dynamics study. |
| 7 | Engineering a High-Affinity Anti-Methoxy Poly(ethylene glycol) (mPEG) Antibody for Sensitive Immunosensing of mPEGylated Therapeutics and mPEG Molecules Engineering a High-Affinity Anti-Methoxy Poly(ethylene glycol) (mPEG) Antibody for Sensitive Immunosensing of mPEGylated Therapeutics and mPEG Molecules |
| 8 | Micro-PET imaging of hepatitis C virus NS3/4A protease activity using a protease-activatable retention probe Micro-PET imaging of hepatitis C virus NS3/4A protease activity using a protease-activatable retention probe |
| 9 | Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group. Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group. |
| 10 | Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy. Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy. |
| 11 | Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice |
| 12 | Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy. Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy. |
| 13 | Ab Locks for Improving the Selectivity and Safety of Antibody Drugs Ab Locks for Improving the Selectivity and Safety of Antibody Drugs |
| 14 | Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes. |
| 15 | 以分子模擬進行 Tsg101 UEV 蛋白與環狀胜肽抑制劑之研究 Cyclic Peptide Inhibitors of the Tsg101 UEV Protein Interactions Refined through Global Docking and Gaussian Accelerated Molecular Dynamics Simulations |
| 16 | Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer |
| 17 | Use of syngeneic cells expressing membrane-bound GM-CSF as an adjuvant to induce antibodies against native multi-pass transmembrane protein Use of syngeneic cells expressing membrane-bound GM-CSF as an adjuvant to induce antibodies against native multi-pass transmembrane protein |
| 18 | 聚乙二醇的IgM和IgG抗體均可以改變甲氧基聚乙二醇-表觀蛋白β在小鼠中的生物活性 Both IgM and IgG Antibodies Against Polyethylene Glycol Can Alter the Biological Activity of Methoxy Polyethylene Glycol-Epoetin Beta in Mice |
| 19 | Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy |
| 20 | 建構可被蛋白酶活化的選擇性抗體 Selective antibody activation through protease-activated proantibodies that mask binding sites with inhibitory domains |
| 21 | Optimization of an Anti-poly(ethylene glycol) (anti-PEG) Cell-Based Capture System To Quantify PEG and PEGylated Molecules Optimization of an Anti-poly(ethylene glycol) (anti-PEG) Cell-Based Capture System To Quantify PEG and PEGylated Molecules |
| 22 | 上皮細胞粘附分子透過激活重編程因子和結腸癌中上皮間質轉化基因表達調節腫瘤起始和腫瘤發生 Epithelial Cell Adhesion Molecule Regulates Tumor Initiation and Tumorigenesis via Activating Reprogramming Factors and Epithelial-Mesenchymal Transition Gene Expression in Colon Cancer |
Project
| NO |
YEAR — Source — No — Type
Project Name
|
Duration |
|---|---|---|
| 1 |
112 — DK 前瞻重點(原校院) — KMU-DK(A)113013 —
探討纖維原樣蛋白加速類風濕性關節炎小鼠模式肺部發炎之機制與治療策略( )
|
2024/01/01 ~ 2024/12/31 |
| 2 |
112 — N 國科會(原科技部) — NSTC112-2628-B-037-001 — 1 個人型
開發蛋白酶可激活之前驅抗原嵌合受體T細胞(Pro-CAR-T)以提升免疫細胞療法對疾病區域之選擇性、抗癌療效並降低副作用(3/3)( )
|
2023/08/01 ~ 2024/07/31 |
| 3 |
111 — DK 前瞻重點(原校院) — KMU-DK(B)112002-1 — 2 整合型
開發前驅抗 ROR1 嵌合受體 T 細胞以治療三陰性乳癌並降低副作用( )
|
2023/01/01 ~ 2023/12/31 |
| 4 |
111 — N 國科會(原科技部) — MOST111-2628-B-037-010 — 1 個人型
開發蛋白酶可激活之前驅抗原嵌合受體T細胞(Pro-CAR-T)以提升免疫細胞療法對疾病區域之選擇性、抗癌療效並降低副作用(2/3)( )
|
2022/08/01 ~ 2023/07/31 |
| 5 |
110 — DK 前瞻重點(原校院) — KMU-DK(B)111004-1 —
探討妙利散益生菌與 β-catenin 抑制劑可轉換免疫活性低腫瘤(cold tumor)為免疫活性 高腫瘤(hot tumor)之機制( )
|
2022/01/01 ~ 2022/12/31 |
| 6 |
110 — N 國科會(原科技部) — MOST110-2628-B-037-010 — 1 個人型
開發蛋白酶可激活之前驅抗原嵌合受體T細胞(Pro-CAR-T)以提升免疫細胞療法對疾病區域之選擇性、抗癌療效並降低副作用(1/3)( )
|
2021/08/01 ~ 2022/07/31 |
| 7 |
110 — NK 高醫-中山合作計畫 — — 2 整合型
以阿茲海默症小鼠動物模式探討對酸鹼度可控的雙功能抗體於活體內之藥物動力學、生物分布與治療療效( )
|
2021/01/01 ~ 2021/12/31 |
| 8 |
110 — Z 大專學生研究計畫及博士後 — MOST111-2813-C-037-031-B — 8 大專學生研究計畫
111年度大專學生研究計畫-鄭瓔(生物3)( )
|
2022/07/01 ~ 2023/02/28 |
| 9 |
109 — DK 前瞻重點(原校院) — KMU-DK(B)110006-3 —
建立商品化anti-PEG抗體檢測ELISA kit來檢測病人血清中anti-PEG抗體含量用以最佳化PEG修飾藥物(Lipo-Dox)之使用( )
|
2021/01/01 ~ 2021/12/31 |
| 10 |
109 — KC 高醫陽明交大 — NCTUKMU109-DR-02 — 1 個人型
以HepG2細胞模式探討抗發炎藥物治療脂肪肝差異表現基因( )
|
2020/08/01 ~ 2021/07/31 |
| 11 |
109 — Z 大專學生研究計畫及博士後 — MOST110-2813-C-037-037-B — 8 大專學生研究計畫
110年度大專學生研究計畫-李佳怡(生技3)( )
|
2021/07/01 ~ 2022/02/28 |
| 12 |
109 — Z 大專學生研究計畫及博士後 — MOST110-2813-C-037-038-B — 8 大專學生研究計畫
110年度大專學生研究計畫-蔡允榛(生技3)( )
|
2021/07/01 ~ 2022/02/28 |
| 13 |
108 — DK 前瞻重點(原校院) — KMU-DK(整)109004~3 —
PolyGlycero修飾藥物的免疫性測試及檢測試劑開發( )
|
2020/01/01 ~ 2020/12/31 |
| 14 |
108 — N 國科會(原科技部) — MOST107-2320-B-037-028-MY2 — 1 個人型
開發可被蛋白酶水解之釋控雙功能抗體以穿透血腦障壁並提升阿茲海默症治療效果(2/2)( )
|
2019/08/01 ~ 2020/07/31 |
| 15 |
108 — NK 高醫-中山合作計畫 — NSYSUKMU108-I008-3 — 2 整合型
利用晶體結構解析高親和力anti-PD-1 抗體-抗原複合物之正確結合位以優化電腦預測系統之精確性( )
|
2019/01/01 ~ 2019/12/31 |
| 16 |
108 — Q 新聘教師計畫(校內) — KMU-Q109002 —
開發Pro-Canakinumab (Pro-anti-IL-1β Ab)前驅抗體藥物選擇性中和病灶區之IL-1β抗原以提升慢性阻塞性肺病療效並降低副作用( )
|
2020/01/01 ~ 2020/12/31 |
| 17 |
108 — Z 大專學生研究計畫及博士後 — MOST109-2813-C-037-043-B — 8 大專學生研究計畫
109年度大專學生研究計畫-方恬芳(生技3)( )
|
2020/07/01 ~ 2021/02/28 |
| 18 |
107 — N 國科會(原科技部) — MOST107-2320-B-037-028-MY2 — 1 個人型
開發可被蛋白酶水解之釋控雙功能抗體以穿透血腦障壁並提升阿茲海默症治療效果(1/2)( )
|
2018/08/01 ~ 2020/07/31 |
| 19 |
107 — Q 新聘教師計畫(校內) — KMU-Q108001 —
利用腫瘤浸潤B細胞開發新穎大腸直腸癌症診斷及治療標的之專一性抗體藥物( )
|
2019/01/01 ~ 2019/12/31 |
| 20 |
107 — Y 高醫-彰基合作計畫 — 108-CCH-KMU-010 — 1 個人型
雙功能抗體(αHER2�~α-mPEG)一步製程賦予糖苷轉換微脂體(GSL)腫瘤專一性，以提升乳癌及卵巢癌之標靶療效( )
|
2019/01/01 ~ 2019/12/31 |
Patent
| NO | Patent Name | Country | Certified Date | Patent No |
|---|---|---|---|---|
| 1 | 二級抗體所辨識之抗原決定位及其用途 | 中華民國 | 2017/08/01 | I593967 |
| 2 | 二級抗體所辨識之抗原決定位及其用途 | 美國 | 2016/10/04 | 9,458,243 |
| 3 | 二級抗體所辨識之抗原決定位及其用途 | 美國 | 2019/01/15 | 10,180,433 |
| 4 | 控制蚊媒傳染疾病傳播之微生物製劑 | 中華民國 | 2021/05/21 | I728264 |